Symbol="BLTE"
AssetType="Common Stock"
Name="Belite Bio Inc ADR"
Description="Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, is engaged in the research and development of novel therapies targeting age-related atrophic macular degeneration and autosomal recessive stargardt diseases. The company is headquartered in San Diego, California."
CIK="1889109"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="12750 HIGH BLUFF DRIVE SUITE 475, SAN DIEGO, CA, CA"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="574475000"
EBITDA="-18576500"
PERatio="None"
PEGRatio="None"
BookValue="1.412"
DividendPerShare="0"
DividendYield="0"
EPS="-0.76"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.256"
ReturnOnEquityTTM="-0.712"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.76"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="45"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="15.48"
EVToRevenue="-"
EVToEBITDA="-91.18"
Beta="None"
num_52WeekHigh="39.85"
num_52WeekLow="11"
num_50DayMovingAverage="16.54"
num_200DayMovingAverage="26.22"
SharesOutstanding="27226300"
DividendDate="None"
ExDividendDate="None"
symbol="BLTE"
open="21.01"
high="22.47"
low="21.01"
price="21.92"
volume="21690.00"
latest_trading_day="2023-08-03"
previous_close="21.10"
change="0.82"
change_percent="3.8863%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="94"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="6"
Volume_recent_avg="39641"
Change_recent_avg="-0.12"
Delta_recent_avg="1.47"
Variance_recent_avg="0.73"
Change_ratio_recent_avg="-0.53"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="6"
Aroon_momentum_negative="94"
image_negative_thumbnail_id_1="107"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0069.jpeg"
image_negative_thumbnail_id_2="1145"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0178.jpeg"
image_neutral_thumbnail_id_1="559"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0040.jpeg"
image_neutral_thumbnail_id_2="542"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0057.jpeg"
image_positive_thumbnail_id_1="993"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0155.jpeg"
image_positive_thumbnail_id_2="614"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0094.jpeg"
image_professor_thumbnail_id_1="1179"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0013.jpeg"
image_professor_thumbnail_id_2="1185"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0019.jpeg"
